CanSino Biologics Inc (CJH) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.066x

Based on the latest financial reports, CanSino Biologics Inc (CJH) has a cash flow conversion efficiency ratio of -0.066x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-392.00 Million ≈ $-458.29 Million USD) by net assets (€5.97 Billion ≈ $6.98 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CanSino Biologics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

CanSino Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how CanSino Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

CanSino Biologics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of CanSino Biologics Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Guizhou Yibai Pharmaceutical Co Ltd SHG:600594	0.015x
Lanner Electronics TWO:6245	0.034x
Raisio Oyj Vaihto-osake HE:RAIVV	0.035x
Zhejiang Talent Television&Film Co Ltd SHE:300426	-0.598x
Laser Tek Taiwan Co Ltd TWO:6207	0.037x
Marine Electricals (India) Limited NSE:MARINE	0.057x
Regulus Resources Inc V:REG	-0.007x
Shanthi Gears Limited NSE:SHANTIGEAR	0.116x

Annual Cash Flow Conversion Efficiency for CanSino Biologics Inc (2016–2025)

The table below shows the annual cash flow conversion efficiency of CanSino Biologics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market value of CanSino Biologics Inc.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€4.95 Billion ≈ $5.79 Billion	€77.86 Million ≈ $91.02 Million	0.016x	+145.72%
2024-12-31	€4.91 Billion ≈ $5.74 Billion	€-168.79 Million ≈ $-197.33 Million	-0.034x	+80.16%
2023-12-31	€5.29 Billion ≈ $6.18 Billion	€-916.25 Million ≈ $-1.07 Billion	-0.173x	+32.19%
2022-12-31	€7.25 Billion ≈ $8.47 Billion	€-1.85 Billion ≈ $-2.16 Billion	-0.256x	-206.55%
2021-12-31	€8.55 Billion ≈ $9.99 Billion	€2.05 Billion ≈ $2.40 Billion	0.240x	+516.06%
2020-12-31	€6.07 Billion ≈ $7.10 Billion	€-349.93 Million ≈ $-409.11 Million	-0.058x	+45.05%
2019-12-31	€1.47 Billion ≈ $1.72 Billion	€-154.25 Million ≈ $-180.33 Million	-0.105x	+57.38%
2018-12-31	€502.32 Million ≈ $587.26 Million	€-123.64 Million ≈ $-144.55 Million	-0.246x	-165.51%
2017-12-31	€607.33 Million ≈ $710.03 Million	€-56.30 Million ≈ $-65.82 Million	-0.093x	+42.17%
2016-12-31	€214.47 Million ≈ $250.74 Million	€-34.38 Million ≈ $-40.20 Million	-0.160x	--

About CanSino Biologics Inc

F:CJH Germany Drug Manufacturers - Specialty & Generic

Market Cap

$375.36 Million

€321.06 Million EUR

Market Cap Rank

#13893 Global

#1408 in Germany

Share Price

€2.42

Change (1 day)

-0.82%

52-Week Range

€2.42 - €5.95

All Time High

€45.99